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Objective: Long-term follow-up after endovascular aneurysm repair (EVAR) is very scarce, and doubt remains regarding
the durability of these procedures. We designed a retrospective cohort study to assess long-term clinical outcome and
morphologic changes in patients with abdominal aortic aneurysms (AAAs) treated by EVAR using the Excluder
endoprosthesis (W. L. Gore and Associates, Flagstaff, Ariz).
Methods: From 2000 to 2007, 179 patients underwent EVAR in a tertiary institution. Clinical data were retrieved from
a prospective database. All patients treated with the Excluder endoprosthesis were included. Computed tomography
angiography (CTA) scans were retrospectively analyzed preoperatively, at 30 days, and at the last follow-up using
dedicated tridimensional reconstruction software. For patients with complications, all remaining CTAs were also
analyzed. The primary end point was clinical success. Secondary end points were freedom from reintervention, sac
growth, types I and III endoleak, migration, conversion to open repair, and AAA-related death or rupture. Neck
dilatation, renal function, and overall survival were also analyzed.
Results: Included were 144 patients (88.2% men; mean age, 71.6 years). Aneurysms were ruptured in 4.9%. American
Society of Anesthesiologists classification was III/IV in 61.8%. No patients were lost during a median follow-up of 5.0
years (interquartile range, 3.1-6.4; maximum, 11.2 years). Two patients died of medical complications <30 days after
EVAR. The estimated primary clinical success rates at 5 and 10 years were 63.5% and 41.1%, and secondary clinical success
rates were 78.3% and 58.3%, respectively. Sac growth was observed in 37 of 142 patients (26.1%). Cox regression showed
type I endoleak during follow-up (hazard ratio, 3.74; P  .008), original design model (hazard ratio, 3.85; P  .001),
and preoperative neck diameter (1.27 per mm increase, P  .006) were determinants of sac growth. Secondary
interventions were required in 32 patients (22.5%). The estimated 10-year rate of AAA-related death or rupture was 2.1%.
Overall life expectancy after AAA repair was 6.8 years.
Conclusions: EVAR using the Excluder endoprosthesis provides a safe and lasting treatment for AAA, despite the need for
maintained surveillance and secondary interventions. At up to 11 years, the risk of AAA-related death or postimplanta-
tion rupture is remarkably low. The incidences of postimplantation sac growth and secondary intervention were greatly
reduced after the introduction of the low-permeability design in 2004. (J Vasc Surg 2012;56:920-8.)
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lTwo decades after its introduction,1 endovascular an-
eurysm repair (EVAR) is established as a valid treatment
option for infrarenal abdominal aortic aneurysms (AAAs).
Compared with open repair, there is evidence of an early
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920urvival benefit at the expense of a higher late reinterven-
ion rate.2-5 As long-term data become available, concerns
ave been raised regarding the durability of EVAR, in
articular, regarding the delayed risk of sac growth and
upture after implantation.6,7
Several endovascular devices are available for AAA re-
air. However, evaluation and comparison of individual
ndoprosthesis is especially difficult due to the lack of
evice-specific reporting in published studies and to the
onstant introduction of improvements and new devices.
his study aims to analyze long-term results and morpho-
ogic changes after EVAR using the Excluder endoprosthe-
is (W. L. Gore and Associates, Flagstaff, Ariz), a device
arketed in Europe since 1997 without major structural
odifications, except for the addition of a low-permeability
xpanded polytetrafluroethylene sleeve to the graft compo-
ition in 2004. Our hypothesis is that EVAR can be per-
ormed with acceptable complication rates and very low
ong-term AAA-related mortality using an endoprosthesis
hat will still be available for the foreseeable future.
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Patient population. Patient selection and data re-
trieval were based on a prospectively kept database of
vascular surgery patients at Erasmus University Medical
Center (Rotterdam, The Netherlands). Inclusion criteria
were date of surgery between January 2000 and December
2007, infrarenal AAA treatment, and implantation of an
Excluder endoprosthesis. Patients with previous aortic sur-
gery or isolated iliac aneurysms were excluded. Vital status
was checked once at the end of follow-up by consult of civil
registry data. All causes of death were obtained. Product
codes of endografts implanted in 2004 were retrieved to
determine which patients received an original design (OD)
or a low-permeability (LP) Excluder.
Image acquisition and postprocessing. Computed
tomography angiography (CTA) was performed according
to standardized institutional protocols. Morphologic anal-
ysis and measurements were performed post hoc using
dedicated U.S. Food and Drug Administration-approved
postprocessing software with center lumen line (CLL) re-
construction (3Mensio Vascular 4.2 software, 3Mensio
Medical Imaging BV, Bilthoven, The Netherlands). CLLs
were constructed semiautomatically and followed the cen-
ter of the aortic and iliac permeable lumen.
All CTA scans were analyzed preoperatively, early (30
days, typically 48 hours) postoperatively, and at the last
follow-up visit. For patients with complications or sac
growth, all other CTAs were also analyzed. No digital
records of preoperative and first postoperative CTAs were
kept for 28 patients (19.4%), and these measurements were
performed on hard copies. Consequently, preoperative and
early postoperative sac volumes were not obtainable for
these patients.
Two observers (A.J., F.G.) performed all image analysis
independently, blinded to patient data. Interobserver vari-
ability was assessed in a sample of 30 patients and agree-
ment was high for AAA diameter (R2 linear 0.996), neck
length (R2 linear 0.991), and neck diameter (R2 linear
0.935). Aneurysm sac volume was assessed according to a
previously published protocol.8
Definitions. Neck length was defined as the length
from the lowermost renal artery to the level where the
aortic diameter increases by at least 10%. Maximum diam-
eter measurements were obtained after CLL reconstruc-
tion. Technical success was defined as successful access and
deployment of an endoprosthesis, without need for open
conversion, type I or III endoleaks, or significant kinking or
obstruction of flow. When an unplanned endovascular pro-
cedure was necessary to obtain success, during the opera-
tion or 24 hours, primary assisted technical success was
considered. When an unplanned open surgical procedure
was necessary, this was considered secondary technical suc-
cess.
Clinical success was defined as successful deployment at
the intended position, without death as a result of treat-
ment, postimplantation rupture, open conversion, type I or
III endoleak, device infection or thrombosis, migration, sac (rowth, or device integrity failure. The distance from the
owermost renal artery to the start of the endoprosthesis
as serially measured and migration calculated using the
rst postoperative measurement as baseline. Migration was
efined as downward displacement of the device by 10
m. A lower threshold of 5 mm was considered separately
ut not accounted for to determine clinical success. Sac
rowth was defined as a diameter increase 5 mm or
olume increase5%. Neck dilatation was considered if the
ifference in neck diameter was 2 mm.
Primary clinical success required no additional or sec-
ndary procedure. In primary assisted clinical success, a
reventive intervention was deemed necessary to maintain
linical success. In secondary clinical success, such a proce-
ure was needed to correct an established complication.
Survival outcomes considered were overall survival and
reedom from AAA-related death or postimplantation rup-
ure. Thirty-day morbidity was defined as any complication
hat required additional procedures or prolonged hospital
tay. All definitions are according to the reporting standards
or EVAR.9
End points. The primary study end point was clinical
uccess. Individual components of clinical success were
sed as secondary end points. These were freedom from
eintervention, sac growth, types I and III endoleak, migra-
ion, conversion to open repair, and AAA-related death or
upture.
Additional analysis. Technical success, early (30-day
r in-hospital) outcome, neck morphology changes, and
verall survival are analyzed. Serum creatinine levels were
btained before surgery, before hospital discharge, and
early thereafter. From these, estimated glomerular filtra-
ion rates (eGFR) were calculated and compared preoper-
tively, early postoperatively, and at the last available
ollow-up.10
Statistical methods. Continuous variables are pre-
ented as means  standard deviation or medians and
nterquartile range, as appropriate. Univariate analysis for
ormally distributed variables was performed using the
tudent t-tests, and for nonparametric variables, Mann-
hitney U tests or Kruskal-Wallis tests were used. Dichot-
mous variables are presented as counts and percentages
nd compared between groups using Pearson 2 statistics
r the Fisher exact test, as applicable. Multivariable logistic
egression analysis was used to identify independent risk
actors for intraoperative type Ia endoleak, and results
eported as odds ratio and 95% confidence intervals (CIs).
aplan-Meier survival curves were used to estimate clinical
uccess and survival, and equality between groups was
ompared with the log-rank (Mantel-Cox) test. Univari-
ble and multivariable Cox proportional hazard analysis
as used to identify risk factors for sac growth and results
eported as hazard ratios and 95% CIs. All statistical tests
ere two-sided and considered significant when the P value
as.05. Analyses were performed using SPSS 19 software
SPSS Inc, Chicago, Ill).
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Study population. From 2000 to 2007, 179 patients
(88.3% men) underwent EVAR for infrarenal AAAs at the
Erasmus University Medical Center. Of these, 144 (80.4%)
were implanted with an Excluder endoprosthesis and in-
cluded in the study. The mean age was 71.6  7.9 years.
Baseline clinical and anatomic characteristics are detailed in
Table I. The following endografts were also used at our
institution during the study period: Zenith (Cook Medical
Inc, Bloomington, Ind) in 27 (15.1%), Lifepath (Edwards
Life Sciences, Irvine, Calif) in four (2.2%), and Talent
(Medtronic, Santa Rosa, Calif) in three (1.7%).
Technical success. The primary technical success rate
of the EVAR procedure was 89.6%, and the primary assisted
success rate was 99.3% (Table II). One conversion to open
repair was performed intraoperatively due to inadvertently
low deployment. The open procedure and postoperative
evolution were uneventful.
Additional intraoperative endovascular procedures
were required in 14 of 144 patients (9.7%). These were due
to type Ia endoleak in nine, type Ib endoleak in two, and
partial occlusion of a renal artery in four. Eight additional
patients were found to have intraoperative type Ia en-
doleak, which resolved with ballooning alone.
A larger preoperative AAA diameter (P  .010) and
Table I. Baseline characteristics
Variablea
Total
(n  144)
Age, years 71.6  8.0
Male sex 127 (88.2)
Hypertension 88 (60.7)
History of CAD 47 (32.6)
Moderate/severe RD 35 (24.3)
Smoking history 84 (58.3)
COPD 35 (24.3)
CVD 13 (9.0)
S-PAD 7 (4.9)
Diabetes 14 (9.7)
ASA score 3 89 (61.8)
RCR index 2 68 (47.2)
Timing of the procedure
Elective 122 (84.7)
Symptomatic 15 (10.4)
Ruptured 7 (4.9)
Anesthesia type
General 54 (37.5)
Regional 76 (52.8)
Local 14 (9.7)
Neck variables
Length, mm 28.5 (21-42)
Diameter, mm 24 (22.2-25)
Angulation,° 27 (14.2-45.7)
AAA variables
Diameter, mm 60 (54-70)
Volume, cm3 185 (150-291)
AAA, Abdominal aortic aneurysm;ASA, American Society of Anesthesiolog
CVD, cerebrovascular disease; LP, low-permeability design; OD, original d
peripheral arterial disease.
aContinuous data are shown as the mean  standard deviation or median (greater infrarenal neck angulation (P  .024) were identi- ied as risk factors for intraoperative type Ia endoleak. Also,
here was a trend toward a higher risk with greater neck
iameters (P  .055). Other baseline anatomic character-
OD
(n  61)
LP
(n  83)
70.5  8.6 72.4  7.5
55 (90.2) 72 (86.7)
39 (63.9) 49 (59.0)
15 (24.6) 32 (38.5)
18 (29.0) 17 (20.5)
36 (59.0) 48 (57.8)
16 (26.2) 19 (23.0)
7 (11.5) 6 (7.2)
4 (6.6) 3 (3.6)
7 (11.5) 7 (8.4)
37 (60.7) 52 (62.6)
25 (41.0) 43 (51.8)
51 (83.6) 71 (85.5)
7 (11.5) 8 (9.6)
3 (4.9) 4 (4.8)
26 (42.6) 28 (33.7)
29 (47.5) 47 (56.6)
6 (9.8) 8 (9.6)
26 (18.5-37.5) 32 (21-44)
24 (23-25) 24 (22-25)
20 (10-37.5) 32 (15-50)
59 (52.5-64) 62 (54-72)
176 (139-267) 192 (155-292)
AD, coronary artery disease;COPD, chronic obstructive pulmonary disease;
; RCR, revised cardiac risk; RD, renal dysfunction; S-PAD, symptomatic
artile range) and categoric data as number (%).
able II. Technical success and 30-day outcome after
ndovascular aneurysm repair
utcome variable
No. (%)
95% CIa(N  144)
echnical success
Primary 129 (89.6) 83.5-93.6
Primary assisted 143 (99.3) 96.2-99.9
ntraoperative conversion to open
repair 1 (0.7) 1.2-3.8
nplanned adjunct proceduresb 14 (9.7) 5.9-15.7
Proximal balloon-expandable
stent 5 (3.5) 1.5-7.9
Proximal cuff 4 (2.8) 1.1-6.9
Renal stenting 4 (2.8) 1.1-6.9
Distal extension 2 (1.4) 0.4-4.9
n-hospital or 30-day death 2 (1.4) 0.4-4.9
Myocardial infarction 1 (0.7) 1.2-3.8
Respiratory infection 1 (0.7) 1.2-3.8
n-hospital or 30-day morbidity 31 (21.5) 15.6-28.9
Graft-related 5 (3.5) 1.5-7.9
Not graft-related 26 (18.1) 12.6-25.1
Confidence intervals (CI) are calculated for the proportions.
Two procedures were performed on the same patient.ists;C
esignstics did not increase risk, nor did the timing of surgery
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only neck diameter was significantly associated with intra-
operative type Ia endoleak (Table III). The presence of
intraoperative type Ia endoleak or the need for adjunct
intraoperative procedures to achieve proximal seal was not
associated with a greater risk of secondary intervention, sac
growth, or migration. This remained true after correcting
for the generation of implanted endoprosthesis.
In-hospital or 30-day mortality and morbidity.
In-hospital or 30-day mortality rate was 1.4% as a result of
two patient deaths, one on day 4 of acute respiratory failure
and one on day 5 of myocardial infarction (Table II). Both
patients were treated in emergency setting due to symp-
tomatic aneurysms.
Five graft-related complications were found in the
postoperative period: three type Ia endoleaks requiring
reintervention (placement of balloon-expandable stents in
two patients and re-ballooning a balloon-expandable stent
placed intraoperatively) and two limb occlusions requiring
surgical thrombectomy and angioplasty with stent place-
ment. Median hospital stay was 3 days (interquartile range,
2-5 days) and three patients (2.1%) were discharged to
another institution.
Clinical success. Median follow-up was 5.0 years (in-
terquartile range, 3.1-6.4; maximum, 11.2 years). No pa-
tients were lost for follow-up, and the exact cause of death
was obtained for all who died. Notably, 43 patients were
available for follow-up more than 6 years after the original
procedure (Table IV). The estimated primary clinical suc-
cess rates were 63.5% and 41.1% at 5 and 10 years, and
secondary clinical success rates were 78.3% and 58.3%,
respectively (Fig 1).
During the follow-up period, 39 secondary interven-
tions were performed in 32 (22.5%) patients. Problems
with the proximal sealing zone were the motif for interven-
tion in 10 patients, comprising seven type Ia endoleaks and
three with increasingly short proximal sealing. Whenever
possible, the sealing zone was extended by use of a proximal
cuff (n  5) or a partially covered NuMED CP balloon-
expandable stent (n  2; Heart Medical Europe BV, Best,
The Netherlands). One patient was converted to aorto-
monoiliac EVAR after 4 years, and two patients underwent
successful open surgical conversion, after 6 months and
10.5 years, due to type Ia endoleak. Nine patients under-
went implantation of limb extensions. A type Ib endoleak
Table III. Multivariable logistic regression analysis of
risk factors for intraoperative type Ia endoleak
Variable HR (95% CI)a P
Neck diameter 1.255 (1.013-1.555) .038
AAA diameter 1.033 (0.990-1.078) .129
Infrarenal angulation 1.015 (0.989-1.042) .252
AAA, Abdominal aortic aneurysm; CI, confidence interval; HR, hazard
ratio.
aHRs and the 95% CIs are presented per unit increase.was identified in four, with imaging evidence in the remain- tng patients showing increasingly short distal sealing (n 
) or progression of aneurysmal dilatation distal to the
ndoprosthesis (n  1).
Postimplantation sac growth was found in 34 of 142
atients. The generation of implanted endoprosthesis (OD
s LP) was significantly associated with the risk of sac
rowth (Fig 2). Neck diameter and occurrence of type I
ndoleak during follow-up were also significant risk factors
or sac growth in univariable and multivariable analysis
Table V).
Elective open surgical conversion was performed in
our patients with continued sac growth, despite absence of
ndoleak, after 1.9, 3.5, 5.5, and 10.3 years. Three of these
ere implanted with the OD design model. Two patients
nderwent relining with less permeable endoprosthesis af-
able IV. Clinical success and long-term outcome
utcome variable No. (%)
linical success
Primary clinical success 93/144 (64.6)
Primary assisted 99/144 (68.7)
Secondary 115/144 (79.9)
ndograft migration
5 mm 14/142 (9.9)
10 mm 5/142 (3.5)
ac growth
5 mm in diameter 34/142 (23.9)
5% in volume 31/116 (26.7)
Without endoleak 16/142 (11.3)
With endoleak
Type II 12/142 (8.4)
Type I 6/142 (4.2)
econdary endoleak
Type Ia 7/142 (4.9)
Type Ib 4/142 (2.8)
Type II 33/142 (23.2)
econdary interventions
Proximal balloon-expandable stent 2/142 (1.4)
Proximal cuff 5/142 (3.5)
Distal extension 11/142 (7.7)
Open/laparoscopic AAA fenestration 5/142 (3.5)
Open/laparoscopic lumbar/IMA ligation 1/142 (0.7)
Percutaneous embolization of
IMA/lumbars 4/142 (2.8)
Conversion to aortouniiliac 1/142 (0.7)
Conversion to open repair
Elective 6/142 (4.2)
Urgent 1/142 (0.7)
Relining 2/142 (1.4)
Iliac PTA 1/142 (0.7)
ortality (including 30 days) 68/144 (47.2)
AAA-related Mar-68 (4.4)
Oncologic 29/68 (42.6)
Cardiovascular 16/68 (23.5)
Other 20/68 (29.4)
ther secondary graft-related complications
Endograft limb occlusion 2/142 (1.4)
Ischemic colitis 2/142 (1.4)
Buttocks claudication 2/142 (1.4
ostimplantation rupture 1/144 (0.7)
AA, Abdominal aortic aneurysm; IMA, inferior mesenteric artery; PTA,
ercutaneous transluminal angioplasty.er 4.5 and 5.2 years, for similar reasons. These successfully
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derwent endoscopic fenestration, with similar success.
Type II endoleaks were present in 33 of 142 patients
(23.2%). Eight were actively treated by means of open (n
1) or endoscopic (n 2) AAA sac fenestration, endoscopic
lumbar ligation (n  1), or percutaneous lumbar/inferior
mesenteric artery embolization (n  4). Indication for
treatment of type II endoleak was individualized, but asso-
ciation to sac growth was the most common motif for
treatment.
Migration 10 mm was observed in five patients, of
which none had type I endoleak and only one required
secondary intervention due to increasingly short proximal
Fig 1. Kaplan-Meier estimates are shown for primary (solid blue
line), secondary (dashed red line), and primary assisted (dotted blue
line) clinical success (CS). N, Number at risk; SE, standard error.
Fig 2. Kaplan-Meier estimates are shown for sac growth accord-
ing to the low permeability design (solid blue line) and original
design (dashed red line) of implanted endograft. P  .005 (log-
rank test). N, Number at risk; SE, standard error.seal; however, 15 patients were identified when a lower fhreshold of5 mm was used. Two (13.3%) of these had a
ype Ia endoleak and five (33.3%) underwent secondary
ntervention to extend seal. Univariate analysis found mi-
ration increased the risk of secondary type Ia endoleak
P  .042) and the need for secondary proximal neck
ntervention (P  .001). Limb occlusion was observed in
wo patients, of whom one underwent surgical thrombec-
omy, followed by percutaneous transluminal angioplasty,
nd the other remained asymptomatic and was managed
onservatively.
A mean increase of 1.32 mm (95% CI, 1.05-1.58 mm)
as observed between preoperative and last neck diameter,
ranslating into a yearly growth rate of 0.24 mm. Neck
ilatation was observed in 52 patients (36.6%). In 29
atients with 7 years of follow-up, neck dilatation was
resent in 19 (65.5%). Mean oversizing in patients with
eck dilatation was 14.6%  6.0% vs 11.6%  6.6% for
hose without neck dilatation (P  .008). Proximal graft
iameter did not influence dilatation. The presence of neck
ilatation increased the risk of migration 5 mm (odds
atio, 5.5; 95% CI, 1.63-18.23), but no increased risk was
ound for migration 10 mm, occurrence of type Ia en-
oleak, or need for proximal neck secondary intervention.
o relationship was observed between neck dilatation and
ac growth.
One patient sustained rupture at 2.1 years after implan-
ation. This patient had a shrinking aneurysm, from a
1-mm AAA diameter preoperatively to 42 mm at 2 years,
ithout migration or other complications. At the time of
upture, there was clinical and imaging evidence of graft
nfection, later confirmed by positive cultures of Staphylo-
occus aureus. The patient underwent open surgery with
emoval of the infected prosthesis and in situ reconstruc-
ion, but died postoperatively. No other postimplantation
uptures occurred. The estimates for AAA-related death or
upture (including 30 days) were 2.4% at 5 years and 2.4%
t 10 years (Fig 3).
The mean preoperative eGFR was 74.2  25.9 mL/
in/1.73 m2. After surgery, a decline was observed to a
ean eGFR of 69.4  24.5 mL/min/1.73 m2, which
eached statistical significance (P .001). However, at the
ast follow-up visit, the mean eGFR was 73.7  30.5
L/min/1.73 m2, which was not significantly different
able V. A, Cox univariate regression analysis for
eterminants of sac growth
ariable HR (95% CI) P
riginal design model 5.86 (2.77-12.36) .001
ndoleak during follow-up
Type I 2.66 (1.15-6.13) .038
Type II 1.82 (0.89-3.72) .098
eck angulationa 1.003 (0.988-1.018) .707
eck diametera 1.185 (1.021-1.374) .026
I, Confidence interval; HR, hazard ratio.
Per unit increase in endoleak.rom the preoperative mean value (P  .786).
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follow-up. Estimated survival after AAA repair was 6.8 years
(95% CI, 6.1-7.5 years; Fig 3). Only three AAA-related
deaths occurred: two perioperative deaths and one of
infection, as mentioned. The most frequent cause of death
was cancer-related, occurring in 29 of 68 (42.6%), followed
by myocardial infarction in 10 (14.7%) and stroke in six
(8.8%). Overall survival of patients treated urgently was
similar to those treated electively, even when 30-day mor-
tality was included (log-rank P  .117).
DISCUSSION
Despite evidence of an early advantage over open re-
pair, doubt remains regarding the durability of EVAR.6,7
More than two decades after the introduction of the tech-
nique, solid long-term results remain scarce and limited by
the permanent introduction of new devices. The Gore
Excluder endoprosthesis was the preferred device in our
institution for many years and was used in 80% of pa-
tients. Aside from the introduction of the LP design in
2004 and recent developments in the deployment system,
this device has been virtually unchanged since its introduc-
tion. Therefore, our study provides valuable long-term
Table V. B, Cox multivariate regression analysis for determ
Model Variabl
Type I EL during FU Type I EL dur
Plus endograft generation Type I EL dur
Original design
Plus neck diameter Type I EL dur
Original design
Neck diameter
CI, Confidence interval; EL, endoleak; FU, follow-up; HR, hazard ratio.
aPer unit increase in endoleak.
Fig 3. Kaplan-Meier estimates are shown for overall (dashed red
line) and abdominal aortic aneurysm (AAA)-related survival (solid
blue line). EVAR, Endovascular aneurysm repair.information with current clinical applicability. oTechnical success and early results. Intraoperative
djunct procedures were required in 6.2% of patients to
chieve or enhance proximal fixation and seal. Another
.8% were found to have partial occlusion of a renal artery.
hese complications were fundamentally associated with
naccurate deployment. This may have led to a bias in
atient selection toward use of this device in longer proxi-
al necks. It may also explain why, unlike previously re-
orted,11 only neck diameter was associated with intraop-
rative type Ia endoleak.
In-hospital and 30-day mortality was remarkably low
1.4%) for a cohort in which 62% was assessed as American
ociety of Anesthesiologists classes 3 and 4, including
rgent operations. These outcomes compare favorably with
hose of randomized EVAR trials and may result from
election bias.5,12-14
Clinical success. Midterm clinical results using the
xcluder endoprosthesis have been well characterized,15-20
ut long-term clinical outcomes (4 years) are scarce.
ecently, Maleux et al21 published their 10-year experience
ith the Excluder device. Overall, their results are similar to
urs in regard to early success and late complications.
owever, their numbers were smaller (n  121) and in-
luded patients with isolated iliac aneurysms (13%), my-
otic (5%), and pseudoaneurysms (1.7%), which could bias
he overall analysis. Hogg et al22 analyzed the long-term sac
ehavior with the Excluder device, but outcomes were
ompromised by a significant number of patients lost dur-
ng follow-up: after 1 year, only about two-thirds of pa-
ients were available for analysis. To adequately interpret
ong-term results, completeness of follow-up is an essential
rerequisite that our study fulfills.
Long-term results were also recently published for the
alent endoprosthesis.23 They reported similar primary
linical success rate of 64% at 5 years but a much higher
stimated AAA-related mortality of 8% at 7 years and four
ostimplantation ruptures at a mean of 40 months, all
ssociated with graft migration and type I endoleak. An-
ther recent publication reported long-term outcomes us-
ng the Zenith endoprosthesis in 143 elective patients, of
hom four had incomplete imaging data.24 They found
imilar intervention-free survival at 5 years of 77%, but six
ostimplantation ruptures were noted at a mean follow-up
nts of sac growth
HR (95% CI) P
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sac growth. As has been previously reported, the generation
of the implanted device influenced sac growth—OD grafts
increased the risk of sac growth significantly.15,18,19,25 The
large study by Schanzer et al22 reported an overall 41% risk
of sac growth at 5 years; however, no device-specific data
were available. In that study, the chance of growth was
greater from 2004 to 2008, after introduction of the LP
design.
Our results differ, showing a markedly reduced propor-
tion of patients with sac growth after 2004. Accordingly,
Hogg et al reported 14.8% sac growth at 4 years for 301
patients treated with the LP. In our study, volumemeasure-
ments may have introduced a bias, because a larger propor-
tion of patients are classified as having postimplantation sac
growth using volume compared with diameter. Because
postoperative aneurysm sac volume has been shown to
better reflect the efficacy of treatment,26,27 we believe it
provides a more reliable estimate. Importantly, a clear motif
for sac growth (eg, type I endoleak or migration) was found
in all but one patient treated with the LP endoprosthesis.
Conversely, no rupture or AAA-related death was observed
in 13 patients with endotension treated conservatively.
Over time, neck dilatation occurred in one-third of
patients and was associated with the degree of oversizing.
In patients with the longest follow-up, neck dilatation was
very common, reflecting the tendency for continued neck
dilatation over time when self-expanding nitinol grafts are
used. Our data support that long-term dilatation beyond
device diameter is rare, and when present, is associated with
progression of aneurysmal disease.28 Reports on neck dila-
tation differ significantly, perhaps due to institutional pol-
icies on oversizing and device-related characteristics. How-
ever, others have reported higher dilatation rates in devices
with suprarenal fixation, suggesting that as an additional
factor promoting dilatation.29-32
Our cohort had few occlusive complications, occurring
exclusively in patients with narrow aortic bifurcations, a
known risk factor for occlusion.33 Data for European Col-
laborators on Stent-Graft Techniques for Aortic Aneurysm
Repair (EUROSTAR) and single-center reports further
support the good performance of this device in adverse iliac
anatomy,33-35 but this was not directly evaluated in our
population.
Postimplantation rupture has been recognized as the
paradigm of EVAR failure: a report from a large cohort of
Medicare beneficiaries noted a rupture risk of 1.8% at 4
years.36 Subsequently, Wyss et al6 analyzed postimplanta-
tion ruptures from EVAR trial patients and found a rupture
rate of 0.7/100 person-years. They suggested this could
explain the loss of early benefit for EVAR compared with
open repair. Two ruptures occurred in the EVAR trials after
implantation of the Excluder device. In the Veterans Affairs
Open versus Endovascular Repair (OVER) trial, with 327
(37.1%) Excluder devices implanted and a mean follow-up
of 1.8 years, no late ruptures were documented.5 The
same was observed after a median of 6.0 years in the
Dutch Randomised Endovascular Aneurysm Management CDREAM) trial (no device-specific data).4 Several observa-
ional studies analyzing the long-term performance of the
xcluder device have reported no late ruptures.21,22,37-39
ne patient in our series suffered rupture, although this
as caused primarily by endograft infection.
After EVAR, eGFR rates remained stable or slowly
eclined in most patients, despite an intensive CTA surveil-
ance protocol, with a mean decline of 4.8 mL/min/1.73
2 over 5 years. We observed transient worsening of eGFR
fter EVAR and recovery to near-baseline levels at the end
f follow-up. Greenberg et al40 previously described this
-shaped curve, and we confirm their observation over
onger follow-up.
Long-term survival. Our expected survival at 6 years
as close to 50%, which is below the expected rate for the
ame period for the Comparison of Endovascular Aneu-
ysm Repair with Open Repair in Patients with Abdominal
ortic Aneurysm (EVAR-1) and DREAM trials3,4 but
bove the expected survival from the United Kingdom
ndovascular Aneurysm Repair 2 (EVAR-2) trial.2 We
eport an “every-day” population, perhaps resulting in a
ore realistic expectation for clinical practice. Interest-
ngly, most deaths were cancer-related. To further improve
he long-term survival of AAA patients, a more thorough
nd multidisciplinary approach to comorbidities and risk is
esirable.
Limitations. The observational design and single-
enter cohort, with inherent selection bias, limit this study;
owever, unlike most long-term studies, we provide com-
lete follow-up, including cause of death for all patients. As
uch, we avoid omitted complications that never reach
ospital care or get treatment elsewhere. We also acknowl-
dge the relatively small population size.
ONCLUSIONS
This study offers a thorough analysis on clinical out-
ome and morphologic aneurysm changes up to 11 years
fter EVAR using the Excluder endoprosthesis. AAA-
elated mortality was exceptionally low, although clinical
uccess was compromised by a large proportion of sac
rowth in patients treated with the OD generation en-
ografts. Despite continued need for surveillance and in-
ervention, these results provide reassurance for AAA treat-
ent with a currently commercialized endoprosthesis.
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